EP1615912A1 - 4-, 6- oder 7-hydroxyindole mit n-oxidgruppen und deren verwendung als therapeutika - Google Patents

4-, 6- oder 7-hydroxyindole mit n-oxidgruppen und deren verwendung als therapeutika

Info

Publication number
EP1615912A1
EP1615912A1 EP04729109A EP04729109A EP1615912A1 EP 1615912 A1 EP1615912 A1 EP 1615912A1 EP 04729109 A EP04729109 A EP 04729109A EP 04729109 A EP04729109 A EP 04729109A EP 1615912 A1 EP1615912 A1 EP 1615912A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
compounds
aryl
oxopyridin
acid amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04729109A
Other languages
German (de)
English (en)
French (fr)
Inventor
Norbert Höfgen
Hildegard Kuss
Karin Steinike
Ute Egerland
Chris Rundfeldt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elbion GmbH
Original Assignee
Elbion GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion GmbH filed Critical Elbion GmbH
Publication of EP1615912A1 publication Critical patent/EP1615912A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the invention relates to substituted 4-, 6- or 7-hydroxyindoles with N-oxide groups, processes for their preparation, pharmaceutical preparations containing these compounds and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of diseases which are to be influenced by the inhibition of phosphodiesterase 4 activity, in particular in immunocompetent cells (eg macrophages and lymphocytes) by the compounds according to the invention.
  • immunocompetent cells eg macrophages and lymphocytes
  • Adenylate cyclase synthesizes the effective cyclic AMP (cAMP) and cyclic GMP (cGMP) from AMP and GMP. These lead to relaxation in smooth muscle cells, for example, and inhibition of mediator release or synthesis in inflammatory cells.
  • the "second messenger” cAMP and cGMP are degraded by the phosphodiesterases (PDE). So far, 11 families of PDE enzymes (PDE1-11) are known, which differ in their substrate specificity (cAMP, cGMP or both) and the dependence on other substrates (eg calmodulin).
  • PDE Phosphodiesterase inhibitors
  • the inhibition of PDE 4 by suitable inhibitors is therefore regarded as an important approach for the therapy of a large number of allergy-induced diseases (Schudt, Gh., Dent, G., Rabe, K., Phosphodiesterase Inhibitors, Academic Press London 1996).
  • TNF ⁇ tumor necrosis factor ⁇
  • TNF ⁇ tumor necrosis factor ⁇
  • activated macrophages activated T lymphocytes, mast cells, basophils, fibroblasts, endothelial cells and astrocytes in the brain. It has a self-activating effect on neutrophils, eosinophils, fibroblasts and endothelial cells, which releases various tissue-destroying mediators.
  • TNF ⁇ causes the increased production of further pro-inflammatory cytokines, such as GM-CSF (granulocyte-macrophage colony-stimulating factor) or interleukin-8. Due to its inflammatory and catabolic effects, TNF ⁇ plays a central role in a variety of diseases, such as inflammation of the respiratory tract, inflammation of the joints, endotoxic shock, tissue rejection, AIDS and numerous other immunological diseases. Inhibitors of phosphodiesterase 4 are thus also suitable for the therapy of such diseases associated with TNF ⁇ .
  • GM-CSF granulocyte-macrophage colony-stimulating factor
  • interleukin-8 interleukin-8
  • COPD chronic obstructive pulmonary diseases
  • COPD chronic obstructive pulmonary diseases
  • beta2 agonists e.g. salmeterol
  • muscarinergic antagonists e.g. ipratropium
  • neutrophilic granulocytes Regardless of the bacterial infections complicating the disease, there is a chronic inflammation in the bronchi, which is dominated by neutrophilic granulocytes.
  • the mediators and enzymes released by neutrophilic granulocytes are responsible for the observed structural changes in the airways (emphysema). Inhibiting neutrophil granulocyte activity is thus a rational approach to prevent or slow the progression of COPD (deterioration in lung function parameters).
  • An important stimulus for the activation of the granulocytes is the pro-inflammatory cytokine TNF ⁇ (tumor necrosis factor).
  • TNF ⁇ stimulates the formation of oxygen radicals by neutrophilic granulocytes
  • PDE4 inhibitors can very effectively inhibit the release of TNF ⁇ from a large number of cells and thus suppress the activity of the neutrophil granulocytes.
  • the non-specific PDE inhibitor pentoxifylline is able to inhibit both the formation of oxygen radicals and the phagocytosis ability of neutrophil granulocytes (Wenisch, C; Zedtwitz-Liebenstein, K .; Parschalk, B. and Graninger, W .: Effect of pentoxifylline in vitro on neutrophil reactive oxygen production and phagocytic ability assessed by flow cytometry, Clin. Drug Invest, 13 (2): 99-104, 1997).
  • PDE 4 inhibitors are already known. These are primarily xanthine derivatives, rolipram analogs or nitraquazone derivatives (overview in: Karlsson, JA, Aldos, D., Phosphodiesterase 4 inhibitors for the treatment of asthma, Exp. Opin. Ther. Patents 1997, 7: 989-1003). So far, none of these compounds has been brought to clinical use. It had to be found that the known PDE4 inhibitors also have various side effects, such as nausea and emesis, which have not been adequately suppressed so far. It is therefore necessary to discover new PDE4 inhibitors with a better therapeutic index.
  • Patents US 2,825,734 and US 3,188,313 describe various indol-3-ylglyoxylic acid amides which are described in Scheme 1 shown manner. These compounds were used as intermediates for the production of indole derivatives resulting from reductions. Patent US 3,642,803 also describes indol-3-ylglyoxylic acid amides.
  • Farmaco 22 (1967), 229-244 describes the preparation of 5-methoxyindol-3-ylglyoxylic acid amides. Again, the indole derivative used is reacted with oxalyl chloride and the resulting indol-3-ylglyoxylic acid chloride is reacted with an amine.
  • 7-azaindol-3-yl-glyoxylic acid amides are known as PDE4 inhibitors from patent application DE 100 53 275 A1, which also describes their preparation and use as therapeutic agents.
  • the invention relates to substituted hydroxyindoles of the general formula 1,
  • (i) represents -C ⁇ Q -alkyl, straight-chain or branched-chain, optionally mono- or polysubstituted by -OH, -SH, -NH 2 , -NHG, _ 6 -alkyl,
  • Heteroatoms which are preferably N, O and S, the C 6.14 aryl groups and the carbocyclic and heterocyclic substituents in turn optionally, once or more than once, with -C ⁇ alkyl, -OH, -NH 2 , -NH. g alkyl, -N 2 (C alkyl. 1 6), -N0 2, -CN, -F, -Cl, -Br, -I, -OC ⁇ alkyl, -sc. g -alkyl, -S0 3 H,
  • _ 5 alkyl may be substituted, and wherein the alkyl groups on the carbocyclic and heterocyclic substituents in turn optionally one or may be substituted several times with -OH, -SH, -NH 2 , -F, -Cl, -Br, -I, -S0 3 H or / and -COOH, or
  • (ii) represents -C 2.10 alkenyl, mono- or polyunsaturated, straight-chain or branched-chain, optionally mono- or polysubstituted with -OH, -SH, -NH 2 ,
  • NHC NHC ,. 6 alkyl, -N (C 1. 6, alkyl) 2, -NHC M4 -aryl, -N (C6. 14, aryl) 2,
  • -SO.C ⁇ -alkyl, -OS0 2 C, _ 6 -alkyl, -COOH, - (COJC ⁇ -alkyl, -COO-C, _ 5 -alkyl or / and -0 (CO) C, _ 5 - Alkyl can be substituted, and wherein the alkyl groups on the carbocyclic and heterocyclic substituents in turn, if necessary, one or more times with -OH, -SH, -NH 2> -F, -Cl, -Br, -I, -S0 3 H or / and
  • R 2 represents hydrogen or -C ⁇ -3 alkyl
  • R 3 , R 4 and R 5 represent hydrogen or a hydroxyl group, at least one of these substituents representing a hydroxyl group got to,
  • R 6 and R 7 may be the same or different and are for
  • Preferred compounds of formula 1 are those in which R 1 is an optionally substituted one a d radical with a cyclic substituent is particularly preferred.
  • the cyclic substituents are preferably C 3-8 cycloalkyl groups or Cs-e-aryl or heteroaryl radicals which have at least one substituent selected from halogen, ie -F, -Cl, -Br or -I, -OH, -N0 2> - Can carry CN and CF 3 .
  • the invention preferably relates to those compounds in which R 2 represents hydrogen or a methyl group.
  • the invention preferably relates to those compounds in which R 5 represents a hydroxyl group and R 3 and R 4 are hydrogen.
  • the invention preferably relates to those compounds in which at least one of R 6 and R 7 represents a halogen atom.
  • R 6 and R 7 are particularly preferably halogen atoms.
  • the experimental ones are also particularly preferred Examples mentioned compounds.
  • the invention further relates to the physiologically tolerable salts of the compounds of the formula 1.
  • the physiologically tolerable salts are obtained in the usual way by neutralizing the bases with inorganic or organic acids or by neutralizing the acids with inorganic or organic bases.
  • inorganic acids are hydrochloric acid, sulfuric acid, phosphoric acid or hydrobromic acid
  • organic acids are, for example, carboxylic or sulfonic acids, such as acetic acid, tartaric acid, lactic acid, propionic acid, glycolic acid, malonic acid, maleic acid, fumaric acid, tannic acid, succinic acid, alginic acid, benzoic acid, 2 -Phenoxybenzoic acid, 2-acetoxybenzoic acid, cinnamic acid, mandelic acid, citric acid, malic acid, salicylic acid, 3-aminosalicylic acid, ascorbic acid, embonic acid, nicotinic acid, isonicotinic acid, oxalic acid, amino acids, methanesulfonic acid, ethanesulfonic acid,
  • Hydroxyethanesulfonic acid ethane-1, 2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid or naphthalene-2-sulfonic acid.
  • inorganic bases sodium hydroxide solution, potassium hydroxide solution, ammonia and organic bases are amines, but preferably tertiary amines, such as trimethylamine, triethylamine, pyridine, N, N-dimethylaniline, quinoline, isoquinoline, ⁇ -picoline, ⁇ -picoline, ⁇ -picoline , Quinaldine or pyrimidine.
  • physiologically tolerable salts of the compounds of the formula I can be obtained by converting derivatives which have tertiary amino groups in a manner known per se using quaternizing agents into the corresponding quaternary ammonium salts.
  • suitable quaternizing agents are alkyl halides, such as methyl iodide, ethyl bromide and n-propyl chloride, but also aryl alkyl halides, such as benzyl chloride or 2-phenylethyl bromide.
  • the invention relates to the compounds of the formula 1 which contain an asymmetric carbon atom, the D form; the L form and D, L mixtures and, in the case of several asymmetric carbon atoms, the diastereomeric forms.
  • Those compounds of formula 1 which contain asymmetric carbon atoms and which are generally obtained as racemates can be separated into the optically active isomers in a manner known per se, for example using an optically active acid.
  • an optically active starting substance from the outset in which case a corresponding optically active or diastereomeric compound is obtained as the end product.
  • the compounds according to the invention are inhibitors of phosphodiesterase 4. It is therefore the object of this invention that the compounds of the formula 1 and their salts and pharmaceutical preparations which contain these compounds or their salts can be used for the treatment of diseases in which an inhibition of the Phosphodiesterase 4 is useful.
  • These diseases include, for example, joint inflammation including arthritis and rheumatoid arthritis and other arthritic diseases such as rheumatoid spondylitis and osteoarthritis.
  • Other possible uses are the treatment of patients suffering from osteoporosis, sepsis, septic shock, gram-negative sepsis, toxic shock syndrome, respiratory distress syndrome, asthma or other chronic pulmonary diseases, bone resorption diseases or graft rejection reactions or other autoimmune diseases, such as lupus erythematosus, multiple sclerosis, glomerulonephritis and uveitis, insulin-dependent diabetes mellitus and chronic demyelination.
  • the compounds according to the invention can also be used for the therapy of infections, such as viral infections and parasite infections, for example for the therapy of malaria, leishmaniasis, infection-related fever, infection-related muscle pain, AIDS and cachexia, and non-allergic rhinitis.
  • infections such as viral infections and parasite infections
  • malaria for example for the therapy of malaria, leishmaniasis, infection-related fever, infection-related muscle pain, AIDS and cachexia, and non-allergic rhinitis.
  • the compounds according to the invention can also be used for the therapy of hyperproliferative diseases, in particular cancer diseases, for example for the therapy of melanomas, breast cancer, lung cancer, colon cancer, skin cancer and leukemia.
  • the compounds of the invention can also be used as bronchodilators and for the treatment of asthma, e.g. for asthma prophylaxis.
  • the compounds according to formula 1 are also inhibitors of the accumulation of eosinophils and their activity. Accordingly, the compounds of the invention can also be used in diseases in which eosinophils play a role. These diseases include, for example, inflammatory respiratory diseases, such as bronchial asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, eczema, allergic angiitis, inflammation mediated by eosinophils, such as eosinophilic fasciitis, eosinophilic pneumonia and PIE syndrome (pulmonary infiltration with Eosinophilaria), ulcerative colitis, Crohn's disease and proliferative skin diseases such as psoriasis or keratosis.
  • inflammatory respiratory diseases such as bronchial asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, eczema, allergic angiitis, inflammation mediated by eosinophil
  • the object of this invention is that the compounds of formula 1 and their salts also the LPS-induced pulmonary neutrophil Can inhibit infiltration in rats in vivo.
  • the pharmacologically significant properties found prove that the compounds of the formula 1 and their salts and pharmaceutical preparations which contain these compounds or their salts can be used therapeutically for the treatment of chronic obstructive pulmonary diseases.
  • the compounds of the invention also have neuroprotective properties and can be used to treat diseases in which neuroprotection is useful.
  • diseases include senile dementia (Alzheimer 's disease), memory loss, Parkinson 's disease, depression, strokes and intermittent claudication.
  • prostate diseases such as, for example, benign prostate hyperplasia, pollakiuria, nocturia, and the treatment of incontinence, colic triggered by urinary stones and male and female sexual dysfunctions.
  • the compounds according to the invention can also be used to inhibit the development of a drug addiction when repeated use of analgesics, such as morphine, and to reduce the development of tolerance when repeated use of these analgesics.
  • analgesics such as morphine
  • an effective dose of the compounds according to the invention or their salts is used to prepare the medicaments.
  • the dosage of the active ingredients can vary depending on the route of administration, age, weight of the patient, type and severity of the diseases to be treated and similar factors.
  • the daily dose can be given as a single dose to be administered once or divided into 2 or more daily doses and is usually 0.001-100 mg. Daily doses of 0.1-50 mg are particularly preferably administered.
  • Topical, inhalative and intranasal preparations of the compounds according to the invention are particularly preferably used.
  • the usual galenical forms of preparation are used, such as tablets, dragees, capsules, dispersible powders, granules, aqueous solutions, aqueous or oily suspensions, syrups, juices or drops.
  • Solid dosage forms can contain inert ingredients and carriers, e.g. Calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginates, gelatin, guar gum, magnesium or aluminum stearate, methyl cellulose, talc, highly disperse silicas, silicone oil, higher molecular fatty acids (such as stearic acid), agar agar or vegetable or animal fats and Oils, solid high molecular weight polymers (such as polyethylene glycol); Preparations suitable for oral administration can optionally contain additional flavors and / or sweeteners.
  • inert ingredients and carriers e.g. Calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginates, gelatin, guar gum, magnesium or aluminum stearate, methyl cellulose, talc, highly disperse silicas, silicone oil, higher molecular fatty acids (such as stearic acid), agar
  • Liquid pharmaceutical forms can be sterilized and / or optionally contain auxiliaries, such as preservatives, stabilizers, wetting agents, penetrants, emulsifiers, spreading agents, solubilizers, salts, sugars or sugar alcohols, for regulating the osmotic pressure or for buffering and / or viscosity regulators.
  • auxiliaries such as preservatives, stabilizers, wetting agents, penetrants, emulsifiers, spreading agents, solubilizers, salts, sugars or sugar alcohols, for regulating the osmotic pressure or for buffering and / or viscosity regulators.
  • Such additives are, for example, tartrate and citrate buffers, ethanol, complexing agents (such as ethylenediamine-tetraacetic acid and its non-toxic salts).
  • complexing agents such as ethylenediamine-tetraacetic acid and its non-toxic salts.
  • high-molecular-weight polymers can be used, such as liquid polyethylene oxide, microcrystalline celluloses, carboxymethyl celluloses, polyvinyl-pyrrolidones, dextrans or gelatin.
  • Solid carriers are, for example, starch, lactose, mannitol, Methyl cellulose, talc, highly disperse silicic acids, higher molecular fatty acids (such as stearic acid), gelatin, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats, solid high molecular weight polymers, such as polyethylene glycol.
  • Oily suspensions for parenteral or topical applications can include vegetable synthetic or semi-synthetic oils, such as liquid fatty acid esters with 8 to 22 carbon atoms in the fatty acid chains, for example palmitin, laurin, tridecyl, margarine, stearin, arachine, Myristic, behenic, pentadecyl, linoleic, elaidic, brasidic, erucic or oleic acid, which are monohydric to trihydric alcohols containing 1 to 6 carbon atoms, such as methanol, ethanol, propanol, butanol, pentanol or whose isomers, glycol or glycerol are esterified.
  • vegetable synthetic or semi-synthetic oils such as liquid fatty acid esters with 8 to 22 carbon atoms in the fatty acid chains, for example palmitin, laurin, tridecyl, margarine, stearin, arachine, My
  • Such fatty acid esters are, for example, commercially available miglyols, isopropyl myristate, isopropyl palmitate, isopropyl stearate, PEG 6-capric acid, caprylic / capric acid esters of saturated fatty alcohols,
  • Polyoxyethylene glycerol trioleates ethyl oleate, waxy fatty acid esters, such as artificial duckling gland fat, isopropyl coconut fatty acid,
  • Oleic acid oleyl ester Oleic acid oleyl ester, oleic acid decyl ester, lactic acid ethyl ester, dibutyl phthalate, adipic acid diisopropyl ester, polyol fatty acid esters and others.
  • Silicone oils of various viscosities or fatty alcohols such as isotridecyl alcohol, 2-octyldodecanol, cetylstearyl alcohol or oleyl alcohol, fatty acids, such as oleic acid, are also suitable.
  • Vegetable oils such as castor oil, almond oil, olive oil, sesame oil, cottonseed oil, peanut oil or soybean oil can also be used.
  • Suitable solvents, gelling agents and solubilizers are water or water-miscible solvents.
  • alcohols such as ethanol or isopropyl alcohol, benzyl alcohol, 2-octyldodecanol, polyethylene glycols, phthalates, adipates, propylene glycol, glycerol, di- or tripropylene glycol, waxes, methyl cellosolve, cellosolve, ester, morpholines, dioxane, dimethylsulfoxide, tetra-hydrofluoride, dimethyl formamide are suitable. Cyclohexanone etc. Cellulose ethers which can dissolve or swell both in water and in organic solvents, such as, for example, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose or soluble starches, can be used as film formers.
  • Ionic macromolecules are primarily used here, e.g. Sodium carboxymethyl cellulose, polyacrylic acid, polymethacrylic acid and its salts, sodium amylopectin semiglycolate, alginic acid or propylene glycol alginate as the sodium salt, gum arabic, xanthan gum, guar gum or carrageenan.
  • auxiliaries that can be used are: glycerol, paraffin of different viscosities, triethanolamine, collagen, allantoin, novantisol acid.
  • surfactants emulsifiers or wetting agents may also be necessary for the formulation, e.g. Na-lauryl sulfate, fatty alcohol ether sulfates, di-Na-N-lauryl- ⁇ -iminodipropionate, polyoxyethylated castor oil or sorbitan monooleate, sorbitan monostearate, polysorbates (e.g. Tween), cetyl alcohol, lecithin, glycerol monostearate, alkylphenol polyether Cetyltrimethylammonium chloride or mono- / dialkylpolyglycol ether orthophosphoric acid monoethanolamine salts.
  • surfactants emulsifiers or wetting agents
  • emulsifiers or wetting agents may also be necessary for the formulation, e.g. Na-lauryl sulfate, fatty alcohol ether sulfates, di-Na-N-lauryl- ⁇ -iminodipropionat
  • Stabilizers such as montmorillonites, or colloidal silicas to stabilize emulsions or to prevent the breakdown of active substances, such as antioxidants, for example tocopherols or butylhydroxyanisole, or preservatives, such as p-hydroxybenzoic acid esters, may also be necessary to prepare the desired formulations.
  • Preparations for parenteral administration can be in separate dosage unit forms, such as ampoules or vials. Solutions of the active ingredient are preferably used, preferably aqueous solutions and above all isotonic solutions but also suspensions. These injection forms can be made available as a ready-to-use preparation or can be prepared with the desired solvent or suspending agent just before use by mixing the active compound, for example the lyophilisate, optionally with other solid carriers.
  • Intranasal preparations can be present as aqueous or oily solutions or as aqueous or oily suspensions. They can also be present as lyophilisates, which are prepared with the appropriate solvent or suspending agent before use.
  • the preparation, filling and sealing of the preparations takes place under the usual antimicrobial and aseptic conditions.
  • the invention further relates to processes for the preparation of the compounds according to the invention.
  • the compounds of general formula 1 are prepared with the meanings of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 shown above,
  • R 3 R 4 and R 5 are H or -OR 8 , at least one of these substituents must be -OR 8 and R 8 for a leaving group, for example alkyl, cycloalkyl, arylalkyl, acyl, alkoxycarbonyl , Aryloxycarbonyl, aminocarbonyl, N-substituted aminocarbonyl, silyl, sulfonyl groups and complexing agents, such as, for example, compounds of boric acid, phosphoric acid and covalently or coordinatively bound metals, such as zinc, aluminum or copper, are in themselves in a known manner by treatment with an oxidizing agent, for example an organic peracid, preferably with m-chloroperbenzoic acid and / or peracetic acid, to give the compounds of the formula I j according to the invention.
  • R 3 R 4 and R 5 are H or -OR 8 , at least one of these substituents must be -OR 8 , are oxidized.
  • the compounds of formula 1 according to the invention are released by splitting off the leaving group R 8 still contained in R 3 and / or R 4 and / or R 5 .
  • both acids and bases such as, for example, hydrobromic acid, hydrochloric acid or hydroiodic acid or sodium hydroxide solution, potassium hydroxide solution and sodium or sodium hydroxide Potassium carbonate, but also activating Lewis acids, such as AICI 3 , BF 3 , BBr 3 or LiCI, used.
  • the cleavage reaction takes place in the absence or in the presence of additional activators, such as ethane-1, 2-dithiol or benzyl mercaptan, and ether cleavages, by means of hydrogen, under elevated pressure or under atmospheric pressure, in the presence of a suitable catalyst, such as, for example, palladium or iridium catalysts.
  • the compounds according to the invention are strong inhibitors of phosphodiesterase 4. Their therapeutic potential is demonstrated in vivo, for example by inhibiting the late phase asthmatic reaction (eosinophilia) and by inhibiting LPS-induced neutrophilia in rats.
  • PDE4 activity is determined using enzyme preparations from human polymorphonuclear lymphocytes (PMNL). Human blood (buffy coats) was anticoagulated with citrate. The platelet-rich plasma in the supernatant is separated from the erythrocytes and leukocytes by centrifugation at 700 ⁇ g for 20 minutes at room temperature (RT). The PMNLs for the PDE 4 determination are isolated by a subsequent dextran sedimentation and subsequent gradient centrifugation with Ficoll-Paque.
  • PMNL polymorphonuclear lymphocytes
  • the still intact PMNLs are washed twice with PBS and lysed using ultrasound.
  • the supernatant from a one hour centrifugation at 4 ° C at 48000 xg contains the cytosolic fraction of the PDE 4 and is used for the PDE 4 measurements determined.
  • the phosphodiesterase activity is determined using a modified method from Amersham Pharmacia Biotech, a SPA (Scintillation Proximity Assay).
  • the reaction mixtures contain buffer (50 mM Tris-HCl (pH 7.4), 5 mM MgCl 2 , 100 ⁇ M cGMP), the inhibitors in variable concentrations and the corresponding enzyme preparation.
  • the reaction is started by adding the substrate, 0.5 ⁇ M [ 3 H] -cAMP.
  • the final volume is 100 ⁇ l.
  • Test substances are prepared as stock solutions in DMSO.
  • the DMSO concentration in the reaction mixture is 1% v / v. At this DMSO concentration, the PDE activity is not affected.
  • the samples are incubated at 37 ° C. for 30 minutes.
  • the reaction is stopped by adding a defined amount of SPA beads and the samples are measured after one hour in the beta counter.
  • the non-specific enzyme activity (the blank) is determined in the presence of 100 ⁇ M rolipram and subtracted from the test values.
  • the incubation batches of the PDE4 assay contain 100 ⁇ M cGMP in order to inhibit any contamination by the PDE 3.
  • IC 5 o values were determined in the range of 10 -10 to 10 5 M with respect to.
  • the selectivity for PDE types 3, 5 and 7 is a factor of 100 to 10,000.
  • the inhibition of pulmonary eosinophil infiltration by the substances according to the invention is tested on male Brown Norway rats (200-250 g) which are actively sensitized to ovalbumin (OVA).
  • OVA ovalbumin
  • the Sensitization takes place by subcutaneous injections of a suspension of 10 ⁇ g OVA together with 20 mg aluminum hydroxide as adjuvant in 0.5 ml of physiological saline per animal on days 1, 14 and 21.
  • the animals receive Bordetella pertussis vaccine dilution per animal at the same times 0.25 ml injected ip.
  • the animals are placed individually in open 1 liter plexiglass boxes which are connected to a head and nose exposure device.
  • the animals are exposed to an aerosol made from 1.0% ovalbumin suspension (allergen challenge).
  • the ovalbumin aerosol is generated by a nebulizer operated by compressed air (0.2 MPa) (Bird micro nebulizer, Palm Springs CA, USA).
  • the exposure time is 1 hour, whereby normal controls are also nebulized with an aerosol from 0.9% saline solution for 1 hour.
  • test substances are administered intraperitoneally or orally as a suspension in 10% polyethylene glycol 300 and 0.5% 5-hydroxyethyl cellulose 2 hours before the allergen challenge.
  • control groups are treated with the vehicle according to the application form of the test substance.
  • the compounds according to the invention inhibit late-phase eosinophilia by 30% to 100% after intraperitoneal application of 10 mg / kg and by 30% to 75% after oral application of 30 mg / kg.
  • the compounds according to the invention are therefore particularly suitable for the production of medicaments for the treatment of diseases which are associated with the action of eosinophils.
  • the inhibition of pulmonary neutrophil infiltration by the substances according to the invention is tested on male Lewis rats (250-350 g).
  • the animals are placed individually in open 1 liter plexiglass boxes which are connected to a head and nose exposure device.
  • the animals are exposed to an aerosol from a lipopolysaccharide suspension (100 ⁇ g LPS / ml 0.1% hydroxylamine solution) in PBS (LPS provocation).
  • the LPS / hydroxylamine aerosol is generated by a nebulizer operated by compressed air (0.2 MPa) (Bird micro nebulizer, Palm Springs CA, USA).
  • the exposure time is 40 Minutes, with normal controls also being nebulized for 40 minutes with an aerosol of 0.1% hydroxylamine solution in PBS.
  • the percentage inhibition of neutrophilia in the test group treated with the substance is calculated using the following formula:
  • SC Vehicel treated control group challenged with 0.1% hydroxylamine solution
  • LPSC Vehicel treated control group challenged with LPS (100 ⁇ g / ml 0.1% hydroxylamine solution)
  • LPSD substance-treated test group which had been challenged with LPS (100 ⁇ g / ml 0.1% hydroxylamine solution).
  • test substances are administered orally as a suspension in 10% polyethylene glycol 300 and 0.5% 5-hydroxyethyl cellulose 2 hours before the LPS challenge.
  • the control groups are designed according to the Application form of the test substance treated with the Vehicel.
  • the compounds according to the invention inhibit neutrophilia by 30% to 90% after oral administration of 10 mg / kg and are therefore particularly suitable for the production of medicaments for the treatment of diseases which are associated with the action of neutrophils.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
EP04729109A 2003-04-24 2004-04-23 4-, 6- oder 7-hydroxyindole mit n-oxidgruppen und deren verwendung als therapeutika Withdrawn EP1615912A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10318611A DE10318611A1 (de) 2003-04-24 2003-04-24 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
PCT/EP2004/004338 WO2004094405A1 (de) 2003-04-24 2004-04-23 4-, 6- oder 7-hydroxyindole mit n-oxidgruppen und deren verwendung als therapeutika

Publications (1)

Publication Number Publication Date
EP1615912A1 true EP1615912A1 (de) 2006-01-18

Family

ID=33154393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04729109A Withdrawn EP1615912A1 (de) 2003-04-24 2004-04-23 4-, 6- oder 7-hydroxyindole mit n-oxidgruppen und deren verwendung als therapeutika

Country Status (16)

Country Link
US (2) US7067536B2 (https=)
EP (1) EP1615912A1 (https=)
JP (1) JP2006524208A (https=)
KR (1) KR20060021831A (https=)
CN (1) CN1777600A (https=)
AR (1) AR044081A1 (https=)
AU (1) AU2004232482A1 (https=)
BR (1) BRPI0409793A (https=)
CA (1) CA2523048A1 (https=)
DE (1) DE10318611A1 (https=)
MX (1) MXPA05011437A (https=)
NO (1) NO20055517L (https=)
RU (1) RU2005136431A (https=)
TW (1) TW200503693A (https=)
WO (1) WO2004094405A1 (https=)
ZA (1) ZA200507258B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738677A (en) * 2005-06-27 2007-10-16 Elbion Ag Nitro-substituted hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US8884020B2 (en) * 2006-08-07 2014-11-11 Ironwood Pharmaceuticals, Inc. Indole compounds
DK2124944T3 (da) * 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
TR200003130T2 (tr) 1998-04-28 2001-01-22 Arzneimittelwerk Dresden Gmbh Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
CA2459886A1 (en) 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 1-glyoxlylamide indolizines for treating cancer
US20040116462A1 (en) 2002-12-12 2004-06-17 Mitsunori Ono Indolizine compounds
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004094405A1 *

Also Published As

Publication number Publication date
CA2523048A1 (en) 2004-11-04
CN1777600A (zh) 2006-05-24
US7067536B2 (en) 2006-06-27
NO20055517D0 (no) 2005-11-22
MXPA05011437A (es) 2005-12-12
JP2006524208A (ja) 2006-10-26
TW200503693A (en) 2005-02-01
US20040242643A1 (en) 2004-12-02
US20060128758A1 (en) 2006-06-15
AU2004232482A1 (en) 2004-11-04
NO20055517L (no) 2006-01-18
WO2004094405A1 (de) 2004-11-04
RU2005136431A (ru) 2006-03-20
KR20060021831A (ko) 2006-03-08
DE10318611A1 (de) 2004-11-11
BRPI0409793A (pt) 2006-05-30
ZA200507258B (en) 2006-06-28
AR044081A1 (es) 2005-08-24

Similar Documents

Publication Publication Date Title
DE10253426B4 (de) Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
EP1076657B1 (de) Neue hydroxyindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung
EP1330455B1 (de) Neue 7-azaindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung
US7947705B2 (en) 7-azaindoles and the use thereof as therapeutic agents
EP1615911A1 (de) 5-hydroxyindole mit pyridin-n-oxidgruppen und deren verwendung als phosphodiesterase 4 hemmer
EP1615912A1 (de) 4-, 6- oder 7-hydroxyindole mit n-oxidgruppen und deren verwendung als therapeutika
DE19818964A1 (de) Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
DE10053275A1 (de) Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10228132A1 (de) Amide cyclischer Aminosäuren als PDE 4 Inhibitoren
US20060293362A1 (en) Nitro-substituted hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
MXPA00010514A (en) New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ELBION AG

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080082

Country of ref document: HK

RAX Requested extension states of the european patent have changed

Extension state: MK

Payment date: 20050927

Extension state: LV

Payment date: 20050927

Extension state: HR

Payment date: 20050927

Extension state: AL

Payment date: 20050927

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071031

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1080082

Country of ref document: HK